HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

palosentron drug combination netupitant

Also Known As:

netupitant, palosentron drug combination; Akynzeo; fosnetupitant and palonosetron; netupitant - palosentron

Networked: 7 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Bernareggi, Alberto: 1 article (11/2019)
2.	Caccia, Tatiana: 1 article (11/2019)
3.	Chilingirova, Nataliya: 1 article (11/2019)
4.	Kurteva, Galina: 1 article (11/2019)
5.	Rizzi, Giada: 1 article (11/2019)
6.	Stella, Valentino: 1 article (11/2019)
7.	Darmani, Nissar A: 1 article (01/2017)
8.	Lee, Albert S: 1 article (01/2017)
9.	Picca, Andrew J: 1 article (01/2017)
10.	Zhong, Weixia: 1 article (01/2017)

Related Diseases

1.	Vomiting 11/01/2019 - "Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: Prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy." 01/01/2015 - "NEPA (Akynzeo(®)) has recently been approved by the Food and Drug Administration (FDA) to treat nausea and vomiting in patients undergoing cancer chemotherapy. " 12/01/2015 - "An oral fixed combination of netupitant/palonosetron (NEPA; Akynzeo(®)) is available for use in the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). " 04/27/2015 - "Netupitant/palonosetron (Akynzeo) for chemotherapy-induced nausea and vomiting." 03/01/2015 - "Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting."
2.	Nausea 11/01/2019 - "Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: Prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy." 01/01/2015 - "NEPA (Akynzeo(®)) has recently been approved by the Food and Drug Administration (FDA) to treat nausea and vomiting in patients undergoing cancer chemotherapy. " 12/01/2015 - "An oral fixed combination of netupitant/palonosetron (NEPA; Akynzeo(®)) is available for use in the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). " 04/27/2015 - "Netupitant/palonosetron (Akynzeo) for chemotherapy-induced nausea and vomiting." 03/01/2015 - "Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting."
3.	Neoplasms (Cancer) 11/01/2019 - "Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: Prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy." 01/01/2015 - "NEPA (Akynzeo(®)) has recently been approved by the Food and Drug Administration (FDA) to treat nausea and vomiting in patients undergoing cancer chemotherapy. "
4.	Pain (Aches) 12/01/2014 - "Ledipasvir/sofosbuvir (Harvoni) for hepatitis C virus genotype 1 infection; dulaglutide (Trulicity) for glycemic control in type-2 diabetes; netupitant/palonosetron (Akynzeo) for prevention of nausea and vomiting related to chemotherapy; and naloxegol (Movantik) for opioid-induced constipation in patients with chronic noncancer pain. "
5.	Infections 12/01/2014 - "Ledipasvir/sofosbuvir (Harvoni) for hepatitis C virus genotype 1 infection; dulaglutide (Trulicity) for glycemic control in type-2 diabetes; netupitant/palonosetron (Akynzeo) for prevention of nausea and vomiting related to chemotherapy; and naloxegol (Movantik) for opioid-induced constipation in patients with chronic noncancer pain. "

Related Drugs and Biologics

1.	Palonosetron (Aloxi)
2.	netupitant
3.	Antiemetics
4.	dulaglutide
5.	sofosbuvir drug combination ledipasvir
6.	naloxegol

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Glycemic Control